{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:26:06Z","timestamp":1763817966635,"version":"3.45.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Early-stage diagnosis is crucial for the best prognosis in breast cancer. Here, our objective was to compare serum tumor protein p53 (TP53) levels in an Egyptian population with benign breast disease vs breast cancer to investigate the protein\u2019s utility in early detection and intervention, alongside existing tumor-related markers, including carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and CA15.3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled 231 patients in this study: 146 with breast cancer, 50 with benign conditions, and 35 without breast pathology (healthy control individuals). The serum level of TP53, CEA, CA125, and CA15.3 was quantitated using an enzyme-linked immunosorbent assay. Data were examined using the t test, Spearman correlation, and receiver operating characteristic curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with breast cancer showed clinically significant higher serum levels of TP53 than did individuals with benign conditions and healthy control individuals. Elevated TP53 levels were correlated with advanced tumor stage (P &amp;lt;.001) and high-tumor grade (P\u2005&amp;lt;.001). TP53 effectively distinguished between benign disease and early-stage breast cancer, with an area under the curve of 0.88, 73.6% sensitivity, and 78.0% specificity. Multinomial logistic regression analysis showed that combining TP53 with other tumor-related markers improved early breast cancer detection. Both TP53 and CA125 remained significant predictors in this analysis. A new function, the PCA-Index, which combines concentrations of TP53 and CA125, was developed to enhance early detection in early stages (T1-T2) and low grades (1-2) with notable results: areas under the curve of 0.96 and 0.98, a specificity of 90.0%, and sensitivities of 85.7% and 91.7%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The combined detection of TP53 and CA125, the PCA-Index, has important clinical value for early detection of breast cancer with a high degree of sensitivity and specificity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/labmed\/lmaf032","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:33:24Z","timestamp":1748331204000},"page":"707-714","source":"Crossref","is-referenced-by-count":0,"title":["PCA-Index: The combination of serum levels of p53 and CA125 for breast cancer early detection"],"prefix":"10.1093","volume":"56","author":[{"given":"Mohamed","family":"El-Far","sequence":"first","affiliation":[{"name":"Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University , Mansoura ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed R","family":"Abdelhady","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biotechnology Research Center , New Damietta ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Abouzid","sequence":"additional","affiliation":[{"name":"Surgical Oncology Department, Mansoura Oncology Centre, Faculty of Medicine, Mansoura University , Mansoura ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed M","family":"Omran","sequence":"additional","affiliation":[{"name":"Biochemistry Division, Chemistry Department, Faculty of Science, Helwan University , Cairo ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelfattah M","family":"Attallah","sequence":"additional","affiliation":[{"name":"Research and Development Department, Biotechnology Research Center , New Damietta ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"2025112208223849000_CIT0001","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers"},{"key":"2025112208223849000_CIT0002","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"2025112208223849000_CIT0003","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcancer.2020.02.010","article-title":"Epidemiology of breast cancer, a paradigm of the \u201ccommon soil\u201d hypothesis","volume":"72","author":"Iacoviello","year":"2021","journal-title":"Semin Cancer Biol."},{"key":"2025112208223849000_CIT0004","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"2025112208223849000_CIT0005","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"2025112208223849000_CIT0006","first-page":"171","article-title":"A literature review on the imaging methods for breast cancer","volume":"14","author":"Gerami","year":"2022","journal-title":"Int J Physiol, Pathophysiol Pharmacol"},{"key":"2025112208223849000_CIT0007","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1002\/jmri.26291","article-title":"Abbreviated MRI of the Breast: Does It Provide Value","volume":"49","author":"Leithner","year":"2019","journal-title":"J Magn Reson Imaging."},{"key":"2025112208223849000_CIT0008","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3390\/mi14071462","article-title":"Microwave Imaging and Sensing Techniques for Breast Cancer Detection","volume":"14","author":"Wang","year":"2023","journal-title":"Micromachines (Basel)"},{"key":"2025112208223849000_CIT0009","doi-asserted-by":"publisher","first-page":"63963","DOI":"10.18632\/oncotarget.19246","article-title":"Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"2025112208223849000_CIT0010","doi-asserted-by":"publisher","first-page":"e21231","DOI":"10.1097\/MD.0000000000021231","article-title":"Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and\/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltim)."},{"key":"2025112208223849000_CIT0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.molmet.2019.10.002","article-title":"Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer","volume":"33","author":"Lacroix","year":"2020","journal-title":"Mol Metabol"},{"key":"2025112208223849000_CIT0012","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1038\/srep02246","article-title":"The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis","volume":"3","author":"Yang","year":"2013","journal-title":"Sci Rep."},{"issue":"20","key":"2025112208223849000_CIT0013","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.3390\/molecules26206215","article-title":"p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis","volume":"26","author":"Sobhani","year":"2021","journal-title":"Molecules"},{"volume-title":"TNM classification of malignant tumours","year":"2017","author":"Brierley","key":"2025112208223849000_CIT0014"},{"key":"2025112208223849000_CIT0015","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0361-090x(03)00024-2","article-title":"Detection of serum p53 protein in patients with different gastrointestinal cancers","volume":"27","author":"Attallah","year":"2003","journal-title":"Cancer Detect Prev."},{"key":"2025112208223849000_CIT0016","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thoracic Oncol"},{"key":"2025112208223849000_CIT0017","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.cmpb.2021.106432","article-title":"A novel breast cancer diagnosis scheme with intelligent feature and parameter selections","volume":"214","author":"Punitha","year":"2022","journal-title":"Comput Methods Programs Biomed."},{"key":"2025112208223849000_CIT0018","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/s17071572","article-title":"Early diagnosis of breast cancer","volume":"17","author":"Wang","year":"2017","journal-title":"Sensors (Basel)"},{"key":"2025112208223849000_CIT0019","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/bjc.2016.433","article-title":"Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples","volume":"116","author":"Kazarian","year":"2017","journal-title":"Br J Cancer."},{"key":"2025112208223849000_CIT0020","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.3390\/ijms20246241","article-title":"Do mutations turn p53 into an oncogene","volume":"20","author":"Pitolli","year":"2019","journal-title":"Int J Mol Sci ."},{"key":"2025112208223849000_CIT0021","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"key":"2025112208223849000_CIT0022","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ijc.27767","article-title":"Distinct tumor protein p53 mutants in breast cancer subgroups","volume":"132","author":"Dumay","year":"2013","journal-title":"Int J Cancer."},{"key":"2025112208223849000_CIT0023","doi-asserted-by":"publisher","first-page":"908772","DOI":"10.3389\/fphar.2022.908772","article-title":"Post-translational modifications of p53 in ferroptosis: Novel pharmacological targets for cancer therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol."},{"key":"2025112208223849000_CIT0024","first-page":"7","article-title":"Detection of serum anti-p53 antibodies in breast cancer patients","volume":"22","author":"Al-Hassan","year":"2011","journal-title":"Al-Mustansiriyah J Sci"},{"key":"2025112208223849000_CIT0025","first-page":"410","article-title":"Level of total tumor protein 53 in the sera of Iraqi breast cancer patients","volume":"51","author":"Hassan","year":"2010","journal-title":"Iraqi J Sci."},{"key":"2025112208223849000_CIT0026","first-page":"214","article-title":"Serum level of p53 antibody and tissue expression of p53 in breast cancer","volume":"51","author":"Al-Hassan","year":"2010","journal-title":"Iraqi J Sci."},{"key":"2025112208223849000_CIT0027","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/oxfordjournals.annonc.a057798","article-title":"Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer","volume":"1","author":"Kandylis","year":"1990","journal-title":"Ann Oncol."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/6\/707\/63742839\/lmaf032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/6\/707\/63742839\/lmaf032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:22:42Z","timestamp":1763817762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/56\/6\/707\/8198795"}},"subtitle":[],"editor":[{"given":"Jonathan","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,12]]},"published-print":{"date-parts":[[2025,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmaf032","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"type":"print","value":"0007-5027"},{"type":"electronic","value":"1943-7730"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,12]]}}}